Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.

ABSTRACT:

Context

Chronic supraphysiological glucocorticoid therapy controls the androgen excess of 21-hydroxylase deficiency (21OHD) but contributes to the high prevalence of obesity, glucose intolerance, and reduced bone mass in these patients. Abiraterone acetate (AA) is a prodrug for abiraterone, a potent CYP17A1 inhibitor used to suppress androgens in the treatment of prostate cancer.

Objective

The objective of the study was to test the hypothesis that AA added to physiological hydrocortisone and 9α-fludrocortisone acetate corrects androgen excess in women with 21OHD without causing hypertension or hypokalemia.

Design

This was a phase 1 dose-escalation study.

Setting

The study was conducted at university clinical research centers.

Participants

We screened 14

SUBMITTER: Auchus RJ 

PROVIDER: S-EPMC4121028 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature